Clinical efficacy of Fufang Yinhua Jiedu (FFYH) granules in mild COVID-19 and its anti-SARS-CoV-2 mechanism by blocking autophagy through inhibiting the AKT/mTOR signaling pathway
Our results indicate that FFYH not only has good anti-viral activity against SARS-CoV-2 but also has significant efficacy against COVID-19, indicating that FFYH may be a novel complementary option for treating COVID-19.
Authors
- Zhian Tang
- Tieliang Ma (ORCID: https://orcid.org/0000-0002-4797-5601)
- Pinghu Zhang (ORCID: https://orcid.org/0000-0002-7600-4740)
- Wenlei Wang (ORCID: https://orcid.org/0000-0001-6973-1643)
- Xuhua Mao
- Qin Su
- Hailin Wei
- Xiang Chen (ORCID: https://orcid.org/0000-0002-5045-9253)
- Jinqiang Zhuang
- Xiaoyuan Qi
- Guangming Zhou
- Zhihui Zheng
- Feng Yan
- Guohong Qiao
Institutions
- Jiangsu University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Institute of Laboratory Animal Science (CN)
- Yixing People's Hospital (CN)
- Yangzhou University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-16
- DOI
- https://doi.org/10.3389/fphar.2024.1431617
- Citations
- 2
- Primary Topic
- Autophagy in Disease and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- Government of Jiangsu Province